An estimated 15–20% are found to over-express human epidermal growth factor receptor 2 (HER2) [2], and despite advances in treatment, approximately 15–24% will develop metastatic disease after completion of curative-intent treatment, and 3–10% present with de novo metastatic disease [3,4]. Here, ERBB2 is linked to metastatic neoplasm.